EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...
Novo Nordisk (NVO) has released an update. Novo Nordisk has announced recent transactions involving its shares by board members and executives, highlighting an acquisition of 18,634 shares and a sale ...
Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...
Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...
Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback